Selected article for: "animal human and antiviral activity"
Author: Cao, Jianzhong; Forrest, J. Craig; Zhang, Xuming
Title: A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs
  • Cord-id: 79v0hdi9
  • Document date: 2014_11_28
    • ID: 79v0hdi9
    Snippet: With the recent emergence of Middle East Respiratory Syndrome coronavirus in humans and the outbreak of devastating porcine epidemic diarrhea coronavirus in swine, therapeutic intervention is urgently needed. However, anti-coronavirus drugs currently are not available. In an effort to assist rapid development of anti-coronavirus drugs, here we screened the NIH Clinical Collection in cell culture using a luciferase reporter-expressing recombinant murine coronavirus. Of the 727 compounds screened,
    Document: With the recent emergence of Middle East Respiratory Syndrome coronavirus in humans and the outbreak of devastating porcine epidemic diarrhea coronavirus in swine, therapeutic intervention is urgently needed. However, anti-coronavirus drugs currently are not available. In an effort to assist rapid development of anti-coronavirus drugs, here we screened the NIH Clinical Collection in cell culture using a luciferase reporter-expressing recombinant murine coronavirus. Of the 727 compounds screened, 84 were found to have a significant anti-coronavirus effect. Further experiments revealed that 51 compounds blocked virus entry while 19 others inhibited viral replication. Additional validation studies with the top 3 inhibitors (hexachlorophene, nitazoxanide and homoharringtonine) demonstrated robust anti-coronavirus activities (a reduction of 6 to 8 log(10) in virus titer) with an IC(50) ranging from 11 nM to 1.2 μM. Furthermore, homoharringtonine and hexachlorophene exhibited broad antiviral activity against diverse species of human and animal coronaviruses. Since the NIH Clinical Collection consists of compounds that have already been through clinical trials, these small molecule inhibitors have a great potential for rapid development as anti-coronavirus drugs.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and luciferase activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute respiratory syndrome and luciferase activity reduction: 1
    • acute respiratory syndrome and luciferase assay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute respiratory syndrome and luciferase reporter: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and luciferase reporter gene: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and luciferase reporter screen: 1
    • acute respiratory syndrome and luciferase reporter virus: 1, 2, 3, 4
    • acute respiratory syndrome and mab monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • additional study and luciferase reporter: 1
    • loading control and luciferase activity: 1, 2, 3, 4, 5
    • loading control and luciferase assay: 1, 2, 3
    • loading control and luciferase reporter: 1, 2, 3
    • luciferase assay and mab monoclonal antibody: 1, 2
    • luciferase reporter and mab monoclonal antibody: 1, 2, 3
    • luciferase reporter gene and mab monoclonal antibody: 1, 2